Laboratorios Farmaceuticos Rovi, S.A. (LON: 0ILL)

Market Cap	2.66B
Revenue (ttm)	665.09M
Net Income (ttm)	137.30M
Shares Out	n/a
EPS (ttm)	2.57
PE Ratio	19.41
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Jul 8, 2024

Volume	8
Average Volume	1,029
Open	60.05
Previous Close	61.45
Day's Range	60.05 - 60.05
52-Week Range	37.14 - 79.76
Beta	0.44
RSI	48.13
Earnings Date	Feb 25, 2025

About Laboratorios Farmaceuticos Rovi

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women’s health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Nepar...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1946
• Employees: 2,111
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0ILL

Financial Performance

In 2023, Laboratorios Farmaceuticos Rovi's revenue was 829.51 million, an increase of 1.44% compared to the previous year's 817.70 million. Earnings were 170.34 million, a decrease of -14.69%.

Financial numbers in EUR